Met Life Investment Management, LLC Janux Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 16,349 shares of JANX stock, worth $822,518. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,349
Previous 16,349
-0.0%
Holding current value
$822,518
Previous $684,000
8.48%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$461 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$127 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$121 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$118 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$104 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.1B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...